Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,197,260
  • Shares Outstanding, K 101,856
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -384 M
  • EBITDA $ -377 M
  • 60-Month Beta 2.18
  • Price/Sales 22.11
  • Price/Cash Flow N/A
  • Price/Book 2.49

Options Overview Details

View History
  • Implied Volatility 68.37% (+1.37%)
  • Historical Volatility 56.91%
  • IV Percentile 18%
  • IV Rank 22.86%
  • IV High 122.94% on 02/11/26
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 26) 1.52 (4.85%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,389
  • Volume Avg (30-Day) 563
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 15,952
  • Open Int (30-Day) 14,006
  • Expected Range 29.87 to 32.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.87
  • Number of Estimates 6
  • High Estimate $-0.08
  • Low Estimate $-1.21
  • Prior Year $-1.24
  • Growth Rate Est. (year over year) +29.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.63 +45.12%
on 03/30/26
32.48 -3.36%
on 04/17/26
+5.56 (+21.53%)
since 03/17/26
3-Month
21.63 +45.12%
on 03/30/26
35.34 -11.18%
on 01/22/26
+0.17 (+0.54%)
since 01/16/26
52-Week
15.35 +104.50%
on 05/30/25
36.44 -13.86%
on 01/12/26
+14.39 (+84.65%)
since 04/17/25

Most Recent Stories

More News
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...

BEAM : 31.39 (+3.49%)
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...

BEAM : 31.39 (+3.49%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and...

BEAM : 31.39 (+3.49%)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated...

BEAM : 31.39 (+3.49%)
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.39 (+3.49%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 43.51 (+5.05%)
ARKX : 33.59 (+0.36%)
NFLX : 97.31 (-9.72%)
META : 688.55 (+1.73%)
ROKU : 116.19 (+3.86%)
TXG : 26.08 (+3.33%)
GTLB : 21.42 (-1.88%)
AVGO : 406.54 (+2.03%)
TWST : 59.81 (+6.37%)
ILMN : 134.50 (+1.34%)
CRCL : 105.91 (-1.44%)
WRD : 8.21 (+2.11%)
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application...

BEAM : 31.39 (+3.49%)
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.39 (+3.49%)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

BEAM : 31.39 (+3.49%)
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 31.39 (+3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 33.45
2nd Resistance Point 32.96
1st Resistance Point 32.18
Last Price 31.39
1st Support Level 30.91
2nd Support Level 30.42
3rd Support Level 29.64

See More

52-Week High 36.44
Last Price 31.39
Fibonacci 61.8% 28.38
Fibonacci 50% 25.90
Fibonacci 38.2% 23.41
52-Week Low 15.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.